



(51) International Patent Classification:

C12N 5/10 (2006.01) *C07K 9/00* (2006.01)
C12N 15/12 (2006.01) *A61K 8/60* (2006.01)
C12N 15/52 (2006.01)

(21) International Application Number:

PCT/US2012/020535

(22) International Filing Date:

6 January 2012 (06.01.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/430,256 6 January 2011 (06.01.2011) US

(71) Applicant (for all designated States except US): **THE JOHNS HOPKINS UNIVERSITY** [US/US]; 3400 North Charles Street, Baltimore, MD 21218 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BETENBAUGH, Michael, J.** [US/US]; 6403 Sharon Road, Baltimore, MD 21239 (US).

(74) Agent: **HAILE, Lisa, A.**; DLA Piper LLP (US), 4365 Executive Drive, Suite 1100, San Diego, CA 92121-2133 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: METHOD OF PRODUCTION OF RECOMBINANT GLYCOPROTEINS WITH INCREASED CIRCULATORY HALF-LIFE IN MAMMALIAN CELLS

(57) Abstract: Provided herein are methods and recombinant expression systems for the production of recombinant glycoproteins that have increased sialic acid content and contain predominantly alpha2-6 sialic acid linkages. Also provided herein are recombinant glycoproteins that have an increased in vivo circulatory half-life. One potential application of the glycoproteins described herein is for the treatment and prophylaxis of poisoning by neurotoxins.

